Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Ipidacrine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE known ✓ | P22303 | 17/20 | 0.91 |
| ▸ | BCHE known ✓ | P06276 | 12/20 | 0.52 |
| ▸ | GRIN1 known ✓ | Q05586 | 7/20 | 0.48 |
| ▸ | GRIN2A known ✓ | Q12879 | 7/20 | 0.48 |
| ▸ | CACNB4 known ✓ | O00305 | 1/20 | 0.48 |
| ▸ | CACNA1A known ✓ | O00555 | 1/20 | 0.48 |
| ▸ | CACNA1G known ✓ | O43497 | 1/20 | 0.48 |
| ▸ | CACNG3 known ✓ | O60359 | 1/20 | 0.48 |
| ▸ | CACNA1F known ✓ | O60840 | 1/20 | 0.48 |
| ▸ | CACNA1H known ✓ | O95180 | 1/20 | 0.48 |
| ▸ | CHRM2 known ✓ | P08172 | 1/20 | 0.48 |
| ▸ | ADRA2A known ✓ | P08913 | 1/20 | 0.48 |
| ▸ | CHRM1 known ✓ | P11229 | 1/20 | 0.48 |
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.48 |
| ▸ | OPRM1 known ✓ | P35372 | 1/20 | 0.48 |
| ▸ | CACNB3 known ✓ | P54284 | 1/20 | 0.48 |
| ▸ | CACNA2D1 known ✓ | P54289 | 1/20 | 0.48 |
| ▸ | CACNG7 known ✓ | P62955 | 1/20 | 0.48 |
| ▸ | CACNA1B known ✓ | Q00975 | 1/20 | 0.48 |
| ▸ | CACNA1D known ✓ | Q01668 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ipidacrine SCHEMBL29751898 | 1.00 | ACHE (0.91) | ACHEMAPK1MEN1KMT2ABPTF | |
| Ipidacrine SCHEMBL7536973 | 0.98 | ACHE (0.95) | ACHEMAPK1MEN1KMT2ABPTF | |
| Ipidacrine SCHEMBL1032513 | 0.98 | ACHE (0.95) | ACHEMAPK1MEN1KMT2ABPTF | |
| Ipidacrine SCHEMBL29382648 | 0.95 | ACHE (1.00) | ACHEMAPK1MEN1KMT2ABPTF | |
| SCHEMBL20681035 | 0.93 | ACHE (0.95) | ACHEMAPK1MEN1KMT2ABPTF | |
| Octaaminoacridine SCHEMBL12507982 | 0.93 | ACHE (1.00) | ACHEMAPK1MEN1KMT2ABPTF | |
| SCHEMBL22021195 | 0.88 | ACHE (0.86) | ACHEMAPK1MEN1KMT2ABPTF | |
| SCHEMBL30162181 | 0.88 | ACHE (0.86) | ACHEMAPK1MEN1KMT2ABPTF | |
| Ipidacrine SCHEMBL7540743 | 0.83 | ACHE (0.76) | ACHEMAPK1MEN1KMT2ABPTF | |
| SCHEMBL9583264 | 0.76 | ACHE (0.67) | ACHEMAPK1MEN1KMT2ABPTF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6433173-B1 | DRUG FOR CENTRAL NERVOUS SYSTEM DISORDERS | NIKKEN CHEMICALS CO., LTD. (JP) | 2002-08-13 | — | — | US | claimed |
| EP-1201656-A1 | PROCESSES FOR THE PREPARATION OF IPIDACRINE OR IPIDACRINE HYDROCHLORIDE HYDRATE | Nikken Chemicals Company, Limited (JP) | 2002-05-02 | — | — | EP | claimed |
| US-5869088-A | PREPARATION CONTAINING FATTY ACID, FATTY ACID ESTER OR ALCOHOL AS ABSORPTION ENHANCER | NIKKEN CHEMICALS CO., LTD (JP) | 1999-02-09 | — | — | US | claimed |
| EP-0793963-A1 | PERCUTANEOUSLY ADMINISTRABLE PREPARATION | Nikken Chemicals Company, Limited (JP) | 1997-09-10 | — | — | EP | claimed |
| US-4735953-A | 9-AMINO-2,3,5,6,7,8-HEXAHYDRO-1H-CYCLOPENTA(B)QUINOLINE MONOHYDRATE HYDROCHLORIDE | NAUCHNO-ISSLEDOVATELSKY I PROEKTNY INSTITUT AZOTNOI PROMYSHLENNOSTI I PRODUKTOV ORGANICHESKOGO SINTEZA (AOGIAP) (RU) | 1988-04-05 | — | — | US | claimed |
| US-4550113-A | 9-Amino-2,3,5,6,7,8-hexahydro-1H-cyclopenta(b)quinoline monohydrate hydrochloride as stimulant of neuro-muscular transmission of smooth muscles | NAUCHNO-ISSLEDOVATELSKY INSTITUT PO BIOLOGICHESKIKM ISPYTANIYAM KHIMICHESKIKH SOEDINENY (SU) | 1985-10-29 | — | — | US | claimed |
| JP-2004292316-A | IMPROVING AGENT FOR ACTIVITY OF DAILY LIVING OF ALZHEIMER'S DEMENTIA | NIKKEN CHEM CO LTD | 2004-10-21 | — | — | JP | disclosed |
| JP-2002255819-A | NEUROTROPHIC FACTOR-LIKE AGENT | NIKKEN CHEM CO LTD | 2002-09-11 | — | — | JP | disclosed |
| JP-2002255820-A | MONOAMINERGIC NERVE-ACTIVATING AGENT | NIKKEN CHEM CO LTD | 2002-09-11 | — | — | JP | disclosed |
| US-6433173-B1 | DRUG FOR CENTRAL NERVOUS SYSTEM DISORDERS | NIKKEN CHEMICALS CO., LTD. (JP) | 2002-08-13 | — | — | US | disclosed |
| US-6433173-B1 | DRUG FOR CENTRAL NERVOUS SYSTEM DISORDERS | NIKKEN CHEMICALS CO., LTD. (JP) | 2002-08-13 | — | — | US | disclosed |
| JP-2002193807-A | AGENT FOR IMPROVING DAILY LIVING ACTIVITY OF PATIENT OF ALZHEIMER'S DEMENTIA | NIKKEN CHEM CO LTD | 2002-07-10 | — | — | JP | disclosed |
| EP-1201656-A1 | PROCESSES FOR THE PREPARATION OF IPIDACRINE OR IPIDACRINE HYDROCHLORIDE HYDRATE | Nikken Chemicals Company, Limited (JP) | 2002-05-02 | — | — | EP | disclosed |
| US-5202440-A | Certain 9-amino-2-(or 4)-oxa 1,2,3,4-tetrahydro- or 1,2,3,4,5,6,7,8-octahydro-acridines | PFIZER INC. (US) | 1993-04-13 | — | — | US | disclosed |
| EP-0326134-A1 | 4-Amino-2,3-disubstituted-6,7-dihydro-5H-1-pyridine derivatives, process for their preparation and medicaments containing them | NAUCHNO-ISSLEDOVATELSKY INSTITUT TEKHNOLOGII I BEZOPASNOSTI LEKARSTVENNYKH SREDSTV (RU) | 1989-08-02 | — | — | EP | disclosed |
| US-4735953-A | 9-AMINO-2,3,5,6,7,8-HEXAHYDRO-1H-CYCLOPENTA(B)QUINOLINE MONOHYDRATE HYDROCHLORIDE | NAUCHNO-ISSLEDOVATELSKY I PROEKTNY INSTITUT AZOTNOI PROMYSHLENNOSTI I PRODUKTOV ORGANICHESKOGO SINTEZA (AOGIAP) (RU) | 1988-04-05 | — | — | US | disclosed |
| US-4735953-A | 9-AMINO-2,3,5,6,7,8-HEXAHYDRO-1H-CYCLOPENTA(B)QUINOLINE MONOHYDRATE HYDROCHLORIDE | NAUCHNO-ISSLEDOVATELSKY I PROEKTNY INSTITUT AZOTNOI PROMYSHLENNOSTI I PRODUKTOV ORGANICHESKOGO SINTEZA (AOGIAP) (RU) | 1988-04-05 | — | — | US | disclosed |
| US-4550113-A | 9-Amino-2,3,5,6,7,8-hexahydro-1H-cyclopenta(b)quinoline monohydrate hydrochloride as stimulant of neuro-muscular transmission of smooth muscles | NAUCHNO-ISSLEDOVATELSKY INSTITUT PO BIOLOGICHESKIKM ISPYTANIYAM KHIMICHESKIKH SOEDINENY (SU) | 1985-10-29 | — | — | US | disclosed |
| US-4550113-A | 9-Amino-2,3,5,6,7,8-hexahydro-1H-cyclopenta(b)quinoline monohydrate hydrochloride as stimulant of neuro-muscular transmission of smooth muscles | NAUCHNO-ISSLEDOVATELSKY INSTITUT PO BIOLOGICHESKIKM ISPYTANIYAM KHIMICHESKIKH SOEDINENY (SU) | 1985-10-29 | — | — | US | disclosed |
| US-4550113-A | 9-Amino-2,3,5,6,7,8-hexahydro-1H-cyclopenta(b)quinoline monohydrate hydrochloride as stimulant of neuro-muscular transmission of smooth muscles | NAUCHNO-ISSLEDOVATELSKY INSTITUT PO BIOLOGICHESKIKM ISPYTANIYAM KHIMICHESKIKH SOEDINENY (SU) | 1985-10-29 | — | — | US | disclosed |